(S (S (VP (VBG Designing) (NP (DT a) (JJ new) (NN drug)))) (VP (VBZ is) (NP (DT a) (ADJP (JJ lengthy) (CC and) (JJ expensive)) (NN process))) (. .))
(S (SBAR (IN As) (S (NP (NP (DT the) (NN space)) (PP (IN of) (NP (JJ potential) (NNS molecules)))) (VP (VBZ is) (ADJP (RB very) (JJ large)) (PRN (-LRB- -LRB-) (NP (JJ 10^23-10^60)) (-RRB- -RRB-))))) (, ,) (NP (NP (DT a) (JJ common) (NN technique)) (PP (IN during) (NP (NN drug) (NN discovery)))) (VP (VBZ is) (S (VP (TO to) (VP (VB start) (PP (IN from) (NP (NP (DT a) (NN molecule)) (SBAR (WHNP (WDT which)) (S (ADVP (RB already)) (VP (VBZ has) (NP (NP (DT some)) (PP (IN of) (NP (DT the) (JJ desired) (NNS properties))))))))))))) (. .))
(S (NP (NP (DT An) (JJ interdisciplinary) (NN team)) (PP (IN of) (NP (NNS scientists)))) (VP (NNS generates) (NP (NP (VBP hypothesis)) (PP (IN about) (NP (NP (DT the) (JJ required) (NNS changes)) (PP (TO to) (NP (DT the) (NN prototype))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN work))) (, ,) (NP (PRP we)) (VP (VBP develop) (NP (NP (DT an) (JJ algorithmic) (NN unsupervised-approach)) (SBAR (WHNP (WDT that)) (S (VP (ADVP (RB automatically)) (VBZ generates) (NP (JJ potential) (NN drug) (NNS molecules)) (PP (VBN given) (NP (DT a) (JJ prototype) (NN drug)))))))) (. .))
(S (NP (PRP We)) (VP (VBP show) (SBAR (IN that) (S (NP (NP (DT the) (NNS molecules)) (VP (VBN generated) (PP (IN by) (NP (DT the) (NN system))))) (VP (VBP are) (NP (NP (JJ valid) (NNS molecules)) (CC and) (ADJP (RB significantly) (JJ different) (PP (IN from) (NP (DT the) (JJ prototype) (NN drug))))))))) (. .))
(S (PP (IN Out) (PP (IN of) (NP (NP (DT the) (NNS compounds)) (VP (VBN generated) (PP (IN by) (NP (DT the) (NN system))))))) (, ,) (NP (PRP we)) (VP (VBD identified) (NP (CD 35) (JJ FDA-approved) (NNS drugs))) (. .))
(S (PP (IN As) (NP (DT an) (NN example))) (, ,) (NP (PRP$ our) (NN system)) (VP (VBD generated) (NP (NP (NNP Isoniazid)) (: -) (NP (NP (CD one)) (PP (IN of) (NP (NP (DT the) (JJ main) (NNS drugs)) (PP (IN for) (NP (NN Tuberculosis)))))))) (. .))
(S (NP (DT The) (NN system)) (VP (VBZ is) (ADVP (RB currently)) (VP (VBG being) (VP (VBN deployed) (PP (IN for) (NP (NP (NN use)) (PP (IN in) (NP (NP (NN collaboration)) (PP (IN with) (NP (JJ pharmaceutical) (NNS companies))))) (SBAR (S (VP (TO to) (VP (ADVP (JJ further)) (VB analyze) (NP (DT the) (JJ additional) (JJ generated) (NNS molecules))))))))))) (. .))
